Neuren Pharmaceuticals Limited
NURPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $216,832 | $231,925 | $14,553 | $3,197 |
| % Growth | -6.5% | 1,493.7% | 355.2% | – |
| Cost of Goods Sold | $32,970 | $26,751 | $10 | $8 |
| Gross Profit | $183,862 | $205,174 | $14,543 | $3,189 |
| % Margin | 84.8% | 88.5% | 99.9% | 99.7% |
| R&D Expenses | $32,970 | $26,751 | $12,712 | $9,516 |
| G&A Expenses | $4,701 | $5,946 | $3,437 | $1,914 |
| SG&A Expenses | $4,701 | $5,946 | $3,427 | $1,906 |
| Sales & Mktg Exp. | $0 | $0 | -$10 | -$8 |
| Other Operating Expenses | $22 | $0 | $0 | $0 |
| Operating Expenses | $37,693 | $32,697 | $16,139 | $11,422 |
| Operating Income | $146,191 | $172,494 | -$1,596 | -$17,749 |
| % Margin | 67.4% | 74.4% | -11% | -555.2% |
| Other Income/Exp. Net | $36,749 | $32,646 | $916 | $9,955 |
| Pre-Tax Income | $182,940 | $205,140 | -$680 | -$7,794 |
| Tax Expense | $40,897 | $48,059 | -$864 | $0 |
| Net Income | $142,043 | $157,081 | $184 | -$7,794 |
| % Margin | 65.5% | 67.7% | 1.3% | -243.8% |
| EPS | 1.09 | 1.24 | 0.002 | -0.066 |
| % Growth | -12.1% | 82,566.7% | 102.3% | – |
| EPS Diluted | 1.09 | 1.2 | 0.001 | -0.066 |
| Weighted Avg Shares Out | 130,783 | 127,070 | 125,966 | 117,770 |
| Weighted Avg Shares Out Dil | 130,780 | 130,768 | 128,909 | 117,770 |
| Supplemental Information | – | – | – | – |
| Interest Income | $11,014 | $5,687 | $391 | $41 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $22 | $17 | $10 | $8 |
| EBITDA | $179,183 | $199,262 | -$722 | -$8,225 |
| % Margin | 82.6% | 85.9% | -5% | -257.3% |